CMG Pharmaceutical Co (058820) Fair Value & Analysis
Healthcare · KR · Market cap 168B KRW
Fair value as of: Jul 6, 2026
From 1 valuation models · updated today
Fair value updated Jul 6, 2026 — revised from 6,135 KRW to 913.42 KRW (−85.1%) since Jun 24, 2026. Share price −19.8% over the past month.
Price vs Fair Value (12 months)
12‑month range 870.00 KRW – 2,160 KRW · fair‑value band 681.66 KRW – 1,363 KRW · the 942.00 KRW price screens above the 913.42 KRW fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
CMG Pharmaceutical Co (058820) currently trades at 942.00 KRW, while our model-based Fair Value estimate is 913.42 KRW — implying the stock looks roughly 3.0% overvalued today. We read business quality at 32/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, CMG Pharmaceutical Co generated revenue of 110B KRW at a net margin of -7.6%. Revenue grew 23.7% year over year. It earns a return on equity of -4.3%. Net debt stands at 65.6B KRW. Fundamentals as of Jul 6, 2026
Our scenario range runs from 681.66 KRW (bear case) to 1,363 KRW (bull case); at 942.00 KRW, the current price sits within that range. The share trades about 58% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside — at -3%, 058820 screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
CMG Pharmaceutical Co., Ltd., a pharmaceutical company, develops and sells oral thin film (OTF) pharmaceuticals in South Korea. It offers Tadalafil OTF products for erectile dysfunction; Entecavir OTF products to treat hepatitis type B; Aripiprazole OTF products for schizophrenia; and Montelukast OTF products to treat asthma and allergic rhinitis. CMG Pharmaceutical Co. Ltd. has a strategic collaboration agreement with Handok Inc. for cancer treatment. The company was formerly known as Skynewpharm Co Ltd and changed its name to CMG Pharmaceutical CO., Ltd. in April 2013. CMG Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Seoul, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
CMG Pharmaceutical Co reported revenue of 105B KRW in FY2025 versus 69.5B KRW in FY2021, a compound +10.9%/yr. Reported net income was −10.1B KRW in FY2025.
Is 058820 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 444.80 | kr 440.64 | -1% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| Cipla Limited CIPLA | ₹1,401 | ₹592.37 | -58% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,098 | ₹507.31 | -54% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,272 | ₹720.15 | -43% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is CMG Pharmaceutical Co (058820) undervalued?
What is the fair value of 058820?
What is the quality score of 058820?
What is the revenue of CMG Pharmaceutical Co (058820)?
What is the net profit margin of 058820?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.